was successfully added to your cart.

All Posts By

MSC Nordics

Team profile: Sara Pittner

By | Company update | No Comments

Sára Pittner joined us in September and time has flown ever since. She has already shown a great commitment to work but what we all are really looking forward too is getting a taste from her commitment to baking the perfect cheesecake. Sara adds experience to the team from previous junior business roles at a global pharma company as well as an important softer side from her volunteer work with chronically ill children. We are happy to have her join us!

My name is Sára Pittner, and I joined the MSC team in September as a senior associate. I have a master’s degree in International Business and Economics with additional focus on health economics and related subjects. My interest has, however, always been weighted to the healthcare field where I have gained hands-on experience from several different roles and companies in e.g. pharma and life sciences.

Before starting at MSC, I was part of the business development team of a global mid-sized pharma company in Hungary focusing on the areas women’s health and the central nervous system; specifically medical devices that support the company’s global portfolio development. At the same company, I also had the opportunity to work as a junior product manager and get familiar with go-to-market strategies, branding guidelines and marketing plans, which gave me a fuller understanding of the complex picture of the product life cycle in pharma.

Previously, I have also worked at an award-winning global data service and consulting company where I was a primary client contact mainly for over-the-counter product manufacturers. I was responsible of ensuring effective communication between the company’s clients and production team, as well as preparing market reviews and reports for the clients – often big companies with local affiliates. The key learning I gained in this role could be summarized as a deep insight into trends and dynamics of the pharmaceutical market.

In the past years, I have also been active as an external evaluator for EIT Health on a project basis, providing support in the multidisciplinary evaluation of tech start-ups in the healthcare field.

”Now, as an economist, I have a genuine interest in catalyzing the best healthcare solutions entering the market.”

As I mentioned earlier, my industry experience has not only been on the business side. I am proud of the volunteer work I have done for chronically ill children. As a volunteer for two different organizations, I visited ill children during their long hospital stay to play board games or help them to learn languages and held playing sessions in super-safe summer camps for them. Spending time with ill children like this was humbling but also important as I enriched my understanding and increased my interest for the life science field.

Now, as an economist, I have a genuine interest in catalyzing the best healthcare solutions entering the market.

I also felt that I was ready to take a step to zoom a little into the big picture and start working in a very specific segment after gaining a more high-level knowledge of pharma and medical devices in previous positions. I found exactly what I was looking for at MSC and in management consulting; working on projects in the biotech industry, at a phase of product development where our support can have a great impact on clients’ progress is something new in my career path.

In my position at MSC, I feel I can learn a lot and have an impact at the same time. I enjoy learning through exciting and tangible projects, as a part of a great team of smart and energized people. MSC provides a perfect environment for my personality, as well as a team that works together to maintain high standards and provide the best solutions for our clients.

Sára Pittner, Senior Associate
LinkedIn >

Our masterclass at LSX 2021 on leveraging Biotech Valuations

By | Company update, Valuation | No Comments

Early September 2021, we held the first valuation masterclass at partnering and investor conference LSX. We heard that it became the most attended class which underlines the high interest of successfully using valuation in out-licensing and investor discussions; and the lack of information tailored to the unique Nordic biotech space. Therefore, we are now also running courses to support biotech executives in better understanding and utilizing biotech valuations in crucial negotiations. Watch the masterclass recording or learn more about our valuation courses below.

Join our Fundamentals of Biotech Valuations course to ace valuations in the unique Nordic biotech space. Next session is on October 13, 2021. Sign up here: https://mscnordics.com/product/biotech-valuations-fundamentals/

Did you miss our Biotech Valuation masterclass at LSX? Check out the recording about using Biotech Valuations to best prepare for out-licensing and investments.